INVOKANA 300 mg, film-coated tablet 30 tablets
Active ingredients: CANAGLIFLOZINE, Canagliflozin hemihydrate
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- INVOKANA 300 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- 30 plaquette(s) thermoformée(s) PVC-Aluminium de 1 comprimé(s)
- Marketing authorisation holder
- JANSSEN CILAG INTERNATIONAL NV
- Reimbursement according to BDPM
- 65 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 3 Jan 2024
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
67448256CIP72767295CIP133400927672958Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| CANAGLIFLOZINEcomprimé | 300 mg · un comprimé | FT |
| CANAGLIFLOZINE HÉMIHYDRATÉcomprimé | 306 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.